A disruptive leap in non-contrast MRA
More than 200 million people worldwide suffer from peripheral arterial disease (PAD).1,2
Contraindication of contrast media makes it challenging to diagnose a large number of these patients.
Overcome these current limitations and enhance your clinical capabilities with QISS, a completely new non-contrast MR Angiography technique.
QISS aids in improving patient safety and compliance for higher accuracy3 and better disease management, while maintaining the diagnostic certainty you need in peripheral MRA exams.
Features & Benefits
Planning and execution of CE-MRA requires a high degree of expertise to prevent venous inflow and other artifacts, caused by suboptimal timing of contrast media injection, for example.
With Set-n-go implementation, "QISS provides an easy-to-handle approach for imaging peripheral arteries with little requirements for further adjustments".1 Additionally, QISS2 offers the potential to save operational costs of up to $180 / patient by omitting disposables, contrast agent and lab tests (GFR).3
The software package for non-contrast enhanced peripheral MR Angiography is based on quiescent interval single-shot imaging.
- ECG triggered
- Robust, 2D non-subtractive technology
- Set-n-go implementation (Dot software add-in) for easy application
- Export all images in one series (Combined View, CT-like)
Our recommendations for optimized scanning results
- Peripheral Angio 36 coil
- Whole Body Option
- Up to two Body 18 coils for extended coverage
About 347 million people worldwide have diabetes.1 In many cases this leads to perihperal artery disease.
"The high prevalance of chronic renal impairment in diabetic patients with PAD and the need for high doses of gadolinium based contrast agents place them at risk for nephrogenic system fibrosis."2
QISS3 provides an accurate non-contrast alternative to CE-MRA for demonstrating clinically significant arterial disease in patients where contrast agents are contraindicated.2,4 Enhance clinical capabilities with access to latest clinical standards of care and improve patient safety with the reduced need for CE-MRA.
"QISS MRA should become the non-contrast MRA technique of choice in patients with renal dysfunction."5
Maria Carr, Research Technologist
Northwestern University Feinberg School of Medicine
QISS publications in MAGNETOM Flash
High Acceleration Quiescent-Interval Single Shot Magnetic Resonance Angiography at 1.5 and 3T
Non-Contrast-Enhanced ECG-Gated Quiescent Interval Single Shot MR Angiography of the Lower Extremities at 3 Tesla: a Case Report
Quiescent-Intervall Single-Shot Magnetic Resonance Angiography
QISS Non-Contrast MR Angiography: A study of Three Cases with Peripheral Vascular Disease
Publications on diabetes
Peripheral arterial disease in patients with diabetes.
QISS publications (1.5 Tesla)
Quiescent-Interval Single-Shot Unenhanced Magnetic Resonance Angiography of Peripheral Vascular Disease: Technical Considerations and Clinical Feasibility
Peripheral arterial disease in a symptomatic diabetic population: prospective comparison of rapid unenhanced MR angiography (MRA) with contrast-enhanced MRA.
Evaluation of peripheral arterial disease with nonenhanced quiescent-interval single-shot MR angiography.
Nonenhanced ECG-gated quiescent-interval single-shot MRA (QISS-MRA) of the lower extremities: comparison with contrast-enhanced MRA.
Comparison of quiescent inflow single-shot and native space for nonenhanced peripheral MR angiography.
QISS publications (3 Tesla)
Nonenhanced peripheral MR-angiography (MRA) at 3 Tesla: evaluation of quiescent-interval single-shot MRA in patients undergoing digital subtraction angiography.
Evaluating Peripheral Arterial Disease With Unenhanced Quiescent-Interval Single-Shot MR Angiography at 3T
Nonenhanced ECG-Gated Quiescent-Interval Single Shot MRA: Image Quality and Stenosis Assessment at 3 Tesla Compared With Contrast-Enhanced MRA and Digital Subtraction Angiography
ECG-gated quiescent-interval single-shot MR angiography of the lower extremities: initial experience at 3 T.
Non-contrast-enhanced MR angiography at 3 Tesla in patients with advanced peripheral arterial occlusive disease.
QISS publications (7 Tesla)
Sequence comparison for non-enhanced MRA of the lower extremity arteries at 7 Tesla
- MAGNETOM Amira
- MAGNETOM Vida
- Biograph mMR
- MAGNETOM Spectra
- MAGNETOM ESSENZA
- MAGNETOM Skyra
- MAGNETOM Aera
- MAGNETOM Prisma
- MAGNETOM Prismafit
- MAGNETOM Skyrafit
- MAGNETOM Avantofit
- MAGNETOM Solafit
- MAGNETOM Vidafit
- MAGNETOM Sola
- MAGNETOM Altea
- MAGNETOM Lumina
Minimum Software Version
syngo MR E11
Additional technical prerequisites may apply. Upon receiving your request, your local Siemens representative will clarify whether your system meets the requirements.
Did this information help you?